215 related articles for article (PubMed ID: 17848948)
1. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
Fanciullino R; Giacometti S; Mercier C; Aubert C; Blanquicett C; Piccerelle P; Ciccolini J
Br J Cancer; 2007 Oct; 97(7):919-26. PubMed ID: 17848948
[TBL] [Abstract][Full Text] [Related]
2. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.
Fanciullino R; Giacometti S; Aubert C; Fina F; Martin PM; Piccerelle P; Ciccolini J
Pharm Res; 2005 Dec; 22(12):2051-7. PubMed ID: 16222443
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer.
Kim SL; Kim SH; Trang KT; Kim IH; Lee SO; Lee ST; Kim DG; Kang SB; Kim SW
Cancer Lett; 2013 Jul; 335(2):479-86. PubMed ID: 23507557
[TBL] [Abstract][Full Text] [Related]
5. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
[TBL] [Abstract][Full Text] [Related]
6. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
7. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
9. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
10. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
Zhang H; Tang J; Li C; Kong J; Wang J; Wu Y; Xu E; Lai M
Cancer Lett; 2015 Jan; 356(2 Pt B):781-90. PubMed ID: 25449431
[TBL] [Abstract][Full Text] [Related]
11. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
[TBL] [Abstract][Full Text] [Related]
12. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
13. Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection.
Jetté L; Bissoon-Haqqani S; Le François B; Maroun JA; Birnboim HC
Anticancer Res; 2008; 28(4B):2175-80. PubMed ID: 18751392
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
Inaba M; Naoe Y; Mitsuhashi J
Biol Pharm Bull; 1998 Jun; 21(6):569-73. PubMed ID: 9657039
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
[TBL] [Abstract][Full Text] [Related]
17. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
[TBL] [Abstract][Full Text] [Related]
18. An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer.
Fan CW; Fan HA; Hsu SH; Chan CC; Chen SY; Hsu YH; Chan EC
Cancer Lett; 2004 Oct; 214(2):181-8. PubMed ID: 15363544
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
20. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]